KOSDAQBiotech & Pharma048530

iNtRON Biotechnology

₩2,445▼ 1.21%2026-11-18 close
Market Cap
₩75.5B
Turnover
₩200M
Volume
100K
Shares out.
30.9M
PER
—
PBR
1.3×
EPS
-₩320
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

SAL200 Retry Continues as Losses Persist

iNtRON Biotechnology is pursuing a new licensing deal for its lead candidate SAL200 and received an IND approval for a nasal-formulation candidate in June 2026, while operating losses have continued for four straight years and the company has posted losses for five consecutive quarters.

  1. 1

    Revenue fell from KRW 14 billion in 2022 to KRW 5.74 billion in 2025, declining for three consecutive years from 2023 through 2025.

  2. 2

    The operating loss widened from KRW 1.48 billion in 2022 to KRW 7.9 billion in 2025, and the company has recorded an operating loss in each year from 2022 through 2025.

  3. 3

    Third-quarter 2026 revenue of KRW 1.83 billion rose 12.5% year on year, and the operating loss narrowed to KRW 1.56 billion.

  4. 4

    SAL200 has seen its rights returned in 2022 and an option left unexercised in 2025, and the company is again seeking a licensing partner.

  5. 5

    The supply arrangement for animal antibiotic alternatives was halted after a damages lawsuit was filed in February 2026.

02

Business structure

iNtRON Biotechnology, founded in 1999, operates a drug-discovery arm and a Diagnosis and Reagents (DR) arm built on bacteriophage-derived technology.

Its drug-discovery arm centers on itLysin, an engineered endolysin platform derived from phage-encoded enzymes, and its lead candidate SAL200 is in development for endocarditis and bacteremia caused by methicillin-resistant Staphylococcus aureus. The mechanism works by breaking down the bacterial cell wall.

The DR arm develops and manufactures PCR and qPCR-based precision diagnostic products and generates practical revenue. A Korean IR research firm analysis from around 2024 showed a revenue split of 60.7% for the DR arm and 39.3% for the drug-discovery arm, and that split may have shifted since.

In 2025, product revenue was 75.41% domestic and 24.59% export. The animal antibiotic alternative business supplied raw material on an exclusive basis to a listed partner, CTC Bio, generating roughly KRW 2.5 billion in annual revenue.

After the company filed a damages lawsuit in February 2026 over alleged contract violations, that supply arrangement was halted.

The company aims to complete a new partner structure by year-end 2026 and restore revenue to about KRW 3 billion in 2027, with a target of KRW 10 billion from this business in 2028 as it expands into companion animal and aquaculture uses. R&D spending is heavy: 2025 R&D expense was KRW 4.66 billion, equal to 81.09% of revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.6B-₩2.1B−127.3%
2025Q4₩1.7B-₩2B−119.8%
2026Q1₩1.9B-₩2.2B−115.0%
2026Q2₩2B-₩1.6B−80.4%
2026Q3₩1.8B-₩1.6B−85.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩14B-₩1.5B₩5.7B−10.6%5.4%32.8%
2023₩9.6B-₩3.3B-₩9.7B−34.3%−10.0%1.9%
2024₩6.4B-₩5.2B-₩2.6B−81.6%−3.1%3.1%
2025₩5.7B-₩7.9B-₩9B−137.7%−12.8%6.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Based on the filed figures, revenue went from KRW 14 billion in 2022 to KRW 9.59 billion in 2023 (down 31.6% year on year), KRW 6.42 billion in 2024 (down 33.0%), and KRW 5.74 billion in 2025 (down 10.6%), declining for three consecutive years from 2023 through 2025. 2022 was the largest year and 2025 the smallest across 2022 to 2025.

The operating loss grew from KRW 1.48 billion in 2022 to KRW 3.28 billion in 2023, KRW 5.24 billion in 2024 and KRW 7.9 billion in 2025, an operating loss in each of the four years from 2022 through 2025. The operating margin moved from -10.6% in 2022 to -34.3% in 2023, -81.6% in 2024 and -137.7% in 2025.

The company cited lower revenue, higher ordinary R&D expense, lower financial income and higher financial costs, and an impairment on an equity-method investment as drivers of the 2025 loss.

Net income attributable to controlling shareholders swung from KRW 5.71 billion in 2022 to a net loss of KRW 9.7 billion in 2023, a loss of KRW 2.59 billion in 2024 and a loss of KRW 8.96 billion in 2025, a loss in each of the three years from 2023 through 2025.

Net income including non-controlling interests moved in the same direction, with a net loss of KRW 8.96 billion in 2025. Operating cash flow fell from KRW 5.98 billion in 2022 and KRW 3.12 billion in 2023 to negative KRW 138 million in 2024 and negative KRW 5.21 billion in 2025.

The debt ratio declined from 32.8% in 2022 to 6.4% in 2025, with total equity of KRW 69.9 billion at year-end 2025.

On a quarterly basis, revenue rose from KRW 1.62 billion in the third quarter of 2025 to KRW 1.7 billion in the fourth quarter (up 5.0% quarter on quarter), KRW 1.88 billion in the first quarter of 2026 (up 10.5%) and KRW 2.03 billion in the second quarter (up 8.1%), then fell to KRW 1.83 billion in the third quarter of 2026 (down 10.2% quarter on quarter) but rose 12.5% year on year.

The operating loss ran at KRW 2.07 billion, KRW 2.04 billion and KRW 2.17 billion over the third and fourth quarters of 2025 and the first quarter of 2026, then narrowed to KRW 1.64 billion in the second quarter and KRW 1.56 billion in the third quarter, a smaller loss year on year.

Among the last five quarters, the fourth quarter of 2025 had the largest net loss attributable to controlling shareholders at KRW 4.15 billion, and the third quarter of 2026 the smallest at KRW 1.33 billion. The four-quarter total for the latest four quarters was KRW 10 billion.

05

Industry analysis

Antimicrobial resistance is an area where infections that no longer respond to existing antibiotics keep demand alive for agents with new mechanisms of action.

Endolysins are described as breaking down the bacterial cell wall, a mechanism that is said to carry a lower likelihood of resistance than synthetic antibiotics.

The value of this technology depends heavily on clinical data and on partners' internal assessments, and two prior arrangements have ended without a completed deal.

In diagnostics, demand surged during the COVID-19 pandemic, but an analysis by a Korean IR research firm noted revenue declines and weaker profitability after the endemic period.

The market for animal antibiotic alternatives is linked to regulatory moves on antibiotic use in livestock, but this company's revenue from that channel has a gap after its partner arrangement was halted.

Life science tools and services stocks came under pressure from cuts to global pharma R&D budgets and funding stress at domestic biotech ventures, according to press reports.

Within that backdrop, iNtRON Biotechnology is viewed as a bacteriophage-platform company, but it is a smaller, platform-based biotech whose business structure differs from peers such as Samsung Biologics and Celltrion, which are built around large pharma and CDMO operations. Pipeline licensing events are therefore the main variable in reading its results more than the sector cycle.

06

Outlook

The company said in June 2026 that a nasal antibacterial candidate based on SAL200 received an IND approval from Korea's MFDS, and in the same month it developed and filed a patent for a subcutaneous-formulation hyaluronidase derived from phage (HAdase).

In March 2026 it secured a phage technology called Drop-in and filed a patent, and in February 2026 it presented complete sterilization data for SAL200 at an AMR conference in Switzerland.

For the SAL200 licensing retry, the company is working to raise production yields, has signed a CDMO work agreement with a domestic partner, and is pursuing a low-cost manufacturing arrangement with Lonza overseas.

On the clinical side, it plans to file a clinical trial plan for SAL200 against Staphylococcus aureus decolonization by year-end 2026. It also plans to secure additional animal study data showing therapeutic superiority in endocarditis to strengthen efficacy support.

For animal antibiotic alternatives, the company is rebuilding with new partners, targeting a return to about KRW 3 billion in revenue in 2027 and a plan to reach KRW 10 billion from this business alone in 2028.

The company also said it presented two abstracts on a microbiome-based colorectal cancer treatment and prevention candidate at ESMO in 2026. Whether and when a licensing deal closes is not a date the company has fixed, so the next checkpoint is whether a partner agreement is disclosed.

07

Valuation

PER
—
PBR
1.3×
ROE
-14.7%
EPS
-₩320
BPS
₩1,946
Dividend per share
₩0

Because the company has recorded net losses attributable to controlling shareholders for the latest four quarters, no earnings-based multiple is calculated.

On a book-value basis, the price-to-book ratio is above 1x, which means the stock carries a premium over net assets, with total equity of KRW 69.9 billion at year-end 2025.

All of that equity belongs to controlling shareholders, and total liabilities of KRW 4.45 billion are small, so the balance sheet itself is not a heavy burden.

Pricing, however, depends more on whether the SAL200 licensing deal closes than on current earnings, so market interpretation could shift sharply with any deal news. Two earlier licensing arrangements ended without completion, and market participants differ on how much pipeline value to assign.

Cash dividends are minimal, so shareholder returns through dividends are limited. The board decided in February 2026 to cancel 1,577,565 treasury shares, and about 722,224 shares were retired in May 2026 as a retirement of treasury stock.

Comparisons with listed biotech peers are most accurate when the diagnostics revenue mix and pipeline stage are considered together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Quarterly revenue rebound and narrower losses in 2026

Third-quarter 2026 revenue of KRW 1.83 billion rose 12.5% year on year, and the operating loss narrowed to KRW 1.56 billion. Revenue also rose quarter on quarter in the first and second quarters of 2026, and the operating loss has narrowed since the second quarter. The revenue base is still small, but the quarterly direction improved during 2026.

Pipeline retry and a new IND approval

SAL200 had its rights returned in June 2022, and a conditional option agreement with Basilea signed in October 2023 lapsed when the option went unexercised in February 2025. The company nevertheless said it received an MFDS IND approval in June 2026 for a nasal antibacterial candidate based on SAL200.

A Korean IR research firm argued that positive SAL200 results could lead to a re-rating of follow-on pipeline assets.

Debt-light balance sheet and cash reserves

Total equity at year-end 2025 was KRW 69.9 billion and total liabilities were KRW 4.45 billion, with the debt ratio falling to 6.4% from 32.8% in 2022. According to an Edaily report, cash and cash equivalents stood at about KRW 32.7 billion at the end of the first quarter of 2026. The company said it intends to fund its R&D from its own resources.

09

Bear factors

Prolonged losses and operating cash outflow

The operating loss reached KRW 7.9 billion in 2025 after four straight years of losses from 2022. Operating cash flow shifted from an inflow of KRW 5.98 billion in 2022 to an outflow of KRW 5.21 billion in 2025.

Losses have continued for five consecutive quarters, and the latest four quarters total KRW 10 billion in net losses attributable to controlling shareholders.

A history of licensing setbacks

SAL200 was the subject of a licensing deal with a Swiss pharmaceutical company in 2018, reported at a value of about USD 667.5 million, but rights were returned in June 2022. A conditional option agreement with Basilea signed in October 2023 also lapsed after the option went unexercised in February 2025.

The company said the setbacks reflected partners' policy decisions rather than technical problems, but commercial results from the pipeline have not yet appeared.

Revenue decline and a halted core contract

Revenue fell from KRW 14 billion in 2022 to KRW 5.74 billion in 2025, declining for three consecutive years from 2023. With the contract behind the animal-health alternatives revenue halted, the target of about KRW 3 billion in 2027 depends on securing new partners. The outcome of the damages lawsuit could also affect the structure of partnerships.

10

Risk factors

Clinical and licensing uncertainty

SAL200 has two prior licensing setbacks, so securing a new partner and advancing clinical work both remain uncertain. The company attributed the 2022 rights return to a partner's decision to stop development because of clinical cost burdens, but that history remains a weight on how the pipeline is valued. Commercialization of early-stage candidates also depends on obtaining proof-of-concept data.

Revenue base and contract risk

A key contract behind the animal-health alternatives business has been halted and a damages lawsuit has been filed. The KRW 3 billion target for 2027 and KRW 10 billion for 2028 are company goals rather than fixed figures. Diagnostics revenue moves quarter to quarter, which keeps earnings volatile.

Cash burn and R&D burden

Operating cash flow was negative KRW 5.21 billion in 2025, so cash continued to flow out. R&D expense of KRW 4.66 billion in 2025 equaled 81.09% of revenue, leaving the cost structure heavily weighted toward research.

Cash and cash equivalents of about KRW 32.7 billion at the end of the first quarter of 2026 provide a buffer, while the CEO said the company has no plans to raise external funds for now.

11

What to watch next

  1. By end-December 2026 (company target)

    Whether a new partner structure for animal antibiotic alternatives is completed after the halted supply contract. It is a precondition for the company's 2027 revenue recovery target of about KRW 3 billion.

  2. By end-December 2026 (company plan)

    Whether the clinical trial plan for SAL200 against Staphylococcus aureus decolonization is filed. A filing would mark the first formal step in expanding the clinical pipeline.

  3. Around mid-February 2027

    The expected timing of the preliminary 2026 full-year results. The 2025 full-year results were disclosed on February 12, 2026. The next checkpoints are whether the revenue decline continued through the fourth quarter of 2026 and whether the operating loss narrowed.

  4. End of March 2027

    The filing deadline for the 2026 annual business report. The fourth-quarter and full-year 2026 figures, including the annual operating margin, will be confirmed in this report.

12

Overall view

iNtRON Biotechnology combines a bacteriophage-based drug pipeline with a diagnostics business. On filed figures, revenue has declined for three consecutive years from 2023, and the operating loss has continued for four consecutive years from 2022.

Revenue rose and the operating loss narrowed year on year in the third quarter of 2026, showing an improving quarterly trend, but net losses attributable to controlling shareholders over the latest four quarters total KRW 10 billion.

The lead candidate SAL200 is being pursued again after two licensing setbacks, and a June 2026 IND approval for a nasal antibacterial candidate has been added to the pipeline. The animal-health alternatives business has a revenue gap after a halted contract and a lawsuit, and the company has set a 2027 recovery target.

On the balance sheet, a debt ratio of 6.4% and total equity of KRW 69.9 billion at year-end 2025 provide a base, but operating cash flow turned to negative KRW 5.21 billion in 2025. Price dynamics depend heavily on whether a licensing deal closes, and the price-to-book ratio is above 1x.

The next checkpoints are the preliminary 2026 full-year results, the 2026 annual business report due by end-March 2027, and whether a new animal-health partner is signed.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. comp.wisereport.co.kr
  3. pharm.edaily.co.kr
  4. saramin.co.kr
  5. intron.co.kr
  6. m.news.nate.com
  7. greened.kr
  8. eduinfom.com
  9. pinpointnews.co.kr
  10. etoday.co.kr
  11. news.nate.com
  12. lab.incruit.com
  13. news.nate.com
  14. catch.co.kr
  15. bbn.kiwoom.com
  16. investing.com
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis